Company / R&D per Share
NovaBay Pharmaceuticals, Inc. R&D per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.01
FY2024
5-year range
$0.00 / $0.09
FY2020-FY2024
Trend
+184.0%
vs FY2023
Sector context
#205 of 207
Health Care
What the data says
Among 207 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 1% for r&d per share. R&D per Share has fluctuated over the past 10 years, ranging from $0.00 in FY2021 to $2.77 in FY2015.
Based on SEC 10-K filings.
0.01 in FY2024 with a 5-year CAGR of +0.2%.
Declined from $0.09 to $0.01 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +104.3%
- 5-Year CAGR
- +0.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 207This company $0.01 Sector average $12.26
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2024, r&d per share increased 184.0% year-over-year.
- Ranks #205 out of 207 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2015.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.01 | +184.0% |
| FY2023 | $0.00 | -96.5% |
| FY2022 | $0.09 | +8383.7% |
| FY2021 | $0.00 | -87.6% |
| FY2020 | $0.01 | -4.4% |
| FY2019 | $0.01 | -44.0% |
| FY2018 | $0.02 | -43.5% |
| FY2017 | $0.03 | -93.2% |
| FY2016 | $0.39 | -85.8% |
| FY2015 | $2.77 | +1204.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026